442 related articles for article (PubMed ID: 28138787)
1. The development of dendritic cell vaccine-based immunotherapies for glioblastoma.
Reardon DA; Mitchell DA
Semin Immunopathol; 2017 Feb; 39(2):225-239. PubMed ID: 28138787
[TBL] [Abstract][Full Text] [Related]
2. Should dendritic cell-based tumor vaccination be incorporated into standard therapy for newly diagnosed glioblastoma patients?
Van Gool S; De Vleeschouwer S
Expert Rev Neurother; 2012 Oct; 12(10):1173-6. PubMed ID: 23082731
[No Abstract] [Full Text] [Related]
3. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients.
Mitchell DA; Batich KA; Gunn MD; Huang MN; Sanchez-Perez L; Nair SK; Congdon KL; Reap EA; Archer GE; Desjardins A; Friedman AH; Friedman HS; Herndon JE; Coan A; McLendon RE; Reardon DA; Vredenburgh JJ; Bigner DD; Sampson JH
Nature; 2015 Mar; 519(7543):366-9. PubMed ID: 25762141
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cell immunotherapy for glioblastoma.
Polyzoidis S; Ashkan K
Expert Rev Anticancer Ther; 2014 Jul; 14(7):761-3. PubMed ID: 24850137
[TBL] [Abstract][Full Text] [Related]
5. Safe and Reproducible Preparation of Functional Dendritic Cells for Immunotherapy in Glioblastoma Patients.
Nava S; Lisini D; Pogliani S; Dossena M; Bersano A; Pellegatta S; Parati E; Finocchiaro G; Frigerio S
Stem Cells Transl Med; 2015 Oct; 4(10):1164-72. PubMed ID: 26273063
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cell vaccines to combat glioblastoma.
Wheeler CJ
Expert Rev Neurother; 2010 Apr; 10(4):483-6. PubMed ID: 20367199
[No Abstract] [Full Text] [Related]
7. Advances and challenges: dendritic cell vaccination strategies for glioblastoma.
Schaller TH; Sampson JH
Expert Rev Vaccines; 2017 Jan; 16(1):27-36. PubMed ID: 27500911
[TBL] [Abstract][Full Text] [Related]
8. Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines.
Goyvaerts C; Breckpot K
J Immunol Res; 2015; 2015():785634. PubMed ID: 26583156
[TBL] [Abstract][Full Text] [Related]
9. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration.
Yu JS; Wheeler CJ; Zeltzer PM; Ying H; Finger DN; Lee PK; Yong WH; Incardona F; Thompson RC; Riedinger MS; Zhang W; Prins RM; Black KL
Cancer Res; 2001 Feb; 61(3):842-7. PubMed ID: 11221866
[TBL] [Abstract][Full Text] [Related]
10. Vaccine strategies for glioblastoma: progress and future directions.
Jackson C; Ruzevick J; Brem H; Lim M
Immunotherapy; 2013 Feb; 5(2):155-67. PubMed ID: 23413907
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cell-based vaccine for the treatment of malignant glioma: a systematic review.
Wang X; Zhao HY; Zhang FC; Sun Y; Xiong ZY; Jiang XB
Cancer Invest; 2014 Nov; 32(9):451-7. PubMed ID: 25259676
[TBL] [Abstract][Full Text] [Related]
12. Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma.
Batich KA; Swartz AM; Sampson JH
Expert Opin Biol Ther; 2015 Jan; 15(1):79-94. PubMed ID: 25327832
[TBL] [Abstract][Full Text] [Related]
13. Current status and future perspectives of dendritic cell-based cancer immunotherapy.
H Yi D; Appel S
Scand J Immunol; 2013 Aug; 78(2):167-71. PubMed ID: 23672402
[TBL] [Abstract][Full Text] [Related]
14. [Vaccine therapy of prostate cancer].
Doehn C; Böhmer T; Sommerauer M; Kausch I; Jocham D
Aktuelle Urol; 2005 Sep; 36(5):407-16. PubMed ID: 16163603
[TBL] [Abstract][Full Text] [Related]
15. Current vaccine trials in glioblastoma: a review.
Xu LW; Chow KK; Lim M; Li G
J Immunol Res; 2014; 2014():796856. PubMed ID: 24804271
[TBL] [Abstract][Full Text] [Related]
16. Emerging immunotherapies for glioblastoma.
Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
[TBL] [Abstract][Full Text] [Related]
17. Heat shock protein-peptide complex in the treatment of glioblastoma.
See AP; Pradilla G; Yang I; Han S; Parsa AT; Lim M
Expert Rev Vaccines; 2011 Jun; 10(6):721-31. PubMed ID: 21692695
[TBL] [Abstract][Full Text] [Related]
18. Immunological challenges for peptide-based immunotherapy in glioblastoma.
Mohme M; Neidert MC; Regli L; Weller M; Martin R
Cancer Treat Rev; 2014 Mar; 40(2):248-58. PubMed ID: 24064197
[TBL] [Abstract][Full Text] [Related]
19. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma.
Yu JS; Liu G; Ying H; Yong WH; Black KL; Wheeler CJ
Cancer Res; 2004 Jul; 64(14):4973-9. PubMed ID: 15256471
[TBL] [Abstract][Full Text] [Related]
20. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme.
De Vleeschouwer S; Fieuws S; Rutkowski S; Van Calenbergh F; Van Loon J; Goffin J; Sciot R; Wilms G; Demaerel P; Warmuth-Metz M; Soerensen N; Wolff JE; Wagner S; Kaempgen E; Van Gool SW
Clin Cancer Res; 2008 May; 14(10):3098-104. PubMed ID: 18483377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
